Keybank National Association OH raised its position in shares of Becton Dickinson and Co (NYSE:BDX) by 2.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 70,137 shares of the medical instruments supplier’s stock after acquiring an additional 1,598 shares during the period. Keybank National Association OH’s holdings in Becton Dickinson and were worth $17,742,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of BDX. Price T Rowe Associates Inc. MD boosted its stake in shares of Becton Dickinson and by 0.4% in the second quarter. Price T Rowe Associates Inc. MD now owns 34,250,739 shares of the medical instruments supplier’s stock valued at $8,631,529,000 after buying an additional 131,536 shares during the period. Vanguard Group Inc. boosted its stake in shares of Becton Dickinson and by 2.3% in the second quarter. Vanguard Group Inc. now owns 23,018,011 shares of the medical instruments supplier’s stock valued at $5,800,769,000 after buying an additional 520,350 shares during the period. Morgan Stanley boosted its stake in shares of Becton Dickinson and by 66.7% in the second quarter. Morgan Stanley now owns 4,887,187 shares of the medical instruments supplier’s stock valued at $1,231,621,000 after buying an additional 1,955,095 shares during the period. Northern Trust Corp boosted its stake in shares of Becton Dickinson and by 1.5% in the second quarter. Northern Trust Corp now owns 3,271,013 shares of the medical instruments supplier’s stock valued at $824,327,000 after buying an additional 47,202 shares during the period. Finally, Bank of America Corp DE boosted its stake in shares of Becton Dickinson and by 4.1% in the second quarter. Bank of America Corp DE now owns 2,901,319 shares of the medical instruments supplier’s stock valued at $731,162,000 after buying an additional 114,398 shares during the period. Institutional investors own 84.29% of the company’s stock.
Several equities research analysts recently issued reports on BDX shares. Piper Jaffray Companies cut their price target on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Wells Fargo & Co cut their target price on Becton Dickinson and from $290.00 to $285.00 and set an “outperform” rating for the company in a research note on Wednesday. Morgan Stanley upped their target price on Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 16th. Finally, ValuEngine cut Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Five analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $266.09.
In related news, SVP Charles R. Bodner sold 1,514 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $260.08, for a total value of $393,761.12. Following the completion of the sale, the senior vice president now directly owns 5,180 shares in the company, valued at $1,347,214.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Alexandre Conroy sold 9,829 shares of the stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $255.06, for a total value of $2,506,984.74. Following the completion of the sale, the executive vice president now owns 16,535 shares of the company’s stock, valued at $4,217,417.10. The disclosure for this sale can be found here. Insiders have sold 32,174 shares of company stock valued at $8,354,013 over the last quarter. Company insiders own 0.12% of the company’s stock.
Shares of NYSE:BDX traded up $0.06 during trading on Friday, hitting $244.64. 961,860 shares of the company were exchanged, compared to its average volume of 1,180,223. The business’s 50 day moving average is $252.19 and its 200-day moving average is $246.80. The company has a market capitalization of $66.59 billion, a P/E ratio of 20.94, a price-to-earnings-growth ratio of 1.62 and a beta of 1.09. The company has a quick ratio of 0.67, a current ratio of 1.19 and a debt-to-equity ratio of 0.85. Becton Dickinson and Co has a 1-year low of $208.62 and a 1-year high of $264.74.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.30 by $0.01. The company had revenue of $4.58 billion during the quarter, compared to the consensus estimate of $4.57 billion. Becton Dickinson and had a net margin of 6.84% and a return on equity of 15.51%. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same period in the prior year, the business earned $2.93 earnings per share. As a group, sell-side analysts anticipate that Becton Dickinson and Co will post 12.58 earnings per share for the current year.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Recommended Story: What is meant by buying and selling pressure?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.